id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S12676 R47907 |
Mari (Levetiracetam), 2022 | Stillborn | throughout pregnancy | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 0.64 [0.01;34.59] C | 0/17 0/11 | 0 | 17 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8980 R30463 |
AlSheikh (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020 | Stillbirth | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
2.29 [0.04;125.50] C excluded (control group) |
0/9 0/20 | 0 | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8981 R30466 |
AlSheikh (Levetiracetam) (Controls unexposed, sick), 2020 | Stillbirth | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 0.88 [0.02;50.20] C | 0/9 0/8 | 0 | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8986 R30516 |
Aydin (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020 | Intrauterine fetal demise | throughout pregnancy | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.68 [0.01;39.07] C excluded (control group) |
0/10 0/7 | 0 | 10 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8987 R30526 |
Aydin (Levetiracetam) (Controls unexposed, sick), 2020 | Intrauterine fetal demise | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 2.26 [0.04;122.79] C | 0/10 0/22 | 0 | 10 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8982 R30472 |
Arkilo (Levetiracetam), 2015 | Stillbirth | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 13.82 [0.60;318.14] C | 2/11 0/24 | 2 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9013 R30660 |
Tomson (Levetiracetam), 2015 | Stillbirths | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.98 [0.12;8.19] C | 1/324 6/1,910 | 7 | 324 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 5 studies | 1.72 [0.43;6.99] | 9 | 371 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Levetiracetam; 2: Levetiracetam) (Controls unexposed, sick; 3: Levetiracetam) (Controls unexposed, sick; 4: Levetiracetam; 5: Levetiracetam;
Asymetry test p-value = 0.8621 (by Egger's regression)
slope=0.1237 (2.3149); intercept=0.2741 (1.4500); t=0.1890; p=0.8621
excluded 8980, 8986